Dr Alex Stevens

Alex joined Sygnature Discovery in September 2022 as the Director of Physical Chemistry, Drug Metabolism, and Pharmacokinetics.

With over 30 years of experience, Alex has focused on ADME and PK throughout his career. His expertise spans therapeutic drug monitoring, in vivo pharmacokinetics, in vitro to in vivo extrapolation, first-time in human clinical studies, drug discovery at GSK, agrochemical discovery and development, ADME, toxicokinetics, toxicology, human safety risk assessment, and portfolio management.

Alex is a strong advocate for utilizing Phys Chem and DMPK knowledge from the earliest stages of the drug discovery process. He emphasizes the importance of influencing chemical design and identifying issues early to enable informed, data-driven decisions regarding the progression of compounds. By continually focusing on the prediction of human dose and the potential for drug-drug interactions, Alex ensures that a clear picture of a drug candidate’s merits is presented as it moves into preclinical development.

Alex holds a BSc in Pharmacology from Sunderland, as well as an MSc and PhD from the Department of Pharmacy at the University of Manchester.